Arterial Roadshow Series III: High-Potential MedTech, Innovative Payment, and Pharma Supply Chain Projects Shine in October

“VCBeat Roadshow Hall” Issue 3: High-Quality Project Showcase, Arriving as Scheduled After a Brief Hiatus.

Following coordination and communication with the VCBeat content team and the project companies, we have selected the following five high-quality projects as featured highlights for the third edition of “VCBeat Roadshow Hall.”

While sourcing high-quality projects, we are actively enhancing our “investment intent” information network with several partner investment institutions to build a more efficient and precise communication bridge between investors and fundraisers.

Beijing Xinshiji Medical has deeply cultivated the field of CT-FFR, building a precision cardiovascular medical imaging diagnosis platform based on artificial intelligence, cloud computing, and big data. The company currently holds multiple core technologies and patented technologies in the field of medical imaging. Its product’s core technical solutions are mature, offering two technical approaches: hemodynamic analysis and machine learning.

The core of the financing project is the non-invasive assessment of coronary ischemic lesions using CT-based fractional flow reserve (FFR). It primarily employs computational simulations on coronary computed tomography angiography (CCTA) data to derive FFR values. Compared with the gold standard invasive FFR, this approach enables non-invasive, cost-effective, and efficient detection of coronary FFR, establishing it as one of the primary diagnostic methods for coronary artery disease. Clinical partner hospitals include Fuwai Hospital, Chaoyang Hospital, Beijing Tongren Hospital, TEDA Cardiovascular Hospital, Sir Run Run Shaw Hospital, Qilu Hospital, and the First Affiliated Hospital of Harbin Medical University, among others.

Financing Plan: Pre-A Round Financing

Financing Amount: RMB 20 million

Financing History: Angel Round RMB 15 million (Shuimu Yide)

Related Link: “Xinshiji Medical: Deepening CT-FFR Expertise for Precise Diagnosis of Coronary Artery Disease, Clinical Trials Expected to Be Completed by Year-End”

https://vcbeat.top/YmFiMDQ5OGYyZTNjMjIzMjVhMjM3NzU4ODg4Nzk0MWM=

Chengdu Yunweikang specializes in novel medical wearable technologies, integrating big data and artificial intelligence applications to provide convenient, efficient, and cost-effective intelligent screening and diagnostic services for the 176 million patients with sleep-disordered breathing—particularly obstructive sleep apnea (OSA)—across China.

The financing project leverages reflective vital signs monitoring technology and an innovative patch-style product form factor. By fully utilizing OSA algorithms and big data capabilities, it enables imperceptible wear for patients while reducing the cost for medical institutions to conduct OSA screening operations, thereby achieving the goal of large-scale population screening beyond previous capacity limits. The team remains committed to continuous innovation, striving to provide patients with an expanding portfolio of products and services that facilitate early screening, diagnosis, treatment, and rehabilitation.

Funding Plan: Series B Financing (Within 2019)

Financing Amount: RMB 20 million

Financing History: Series A Funding of RMB 20 million (2016, Hangzhou Kaitai Capital)

Related Link: “With a consultation rate of less than 0.1%, how does Yunweikang diagnose the ‘invisible killer’ during sleep in a cost-effective manner”

https://vcbeat.top/Article/searchArticle

Henan Yungu Intelligence has long been dedicated to providing comprehensive informatization solutions and customized software services to pharmaceutical distributors, the tertiary terminal market, and medical institutions. Its portfolio includes the well-known “Yaojingling” software and five independently developed “Cloud Product” suites: Cloud Pharma Connect, Cloud Pharma Hub, Cloud Platform, Cloud Pharma Management, and Cloud Terminal. Additionally, it offers six industry-specific solutions: supply chain solution, financial system solution, warehouse management solution, office automation solution, e-commerce operations solution, and smart pharmacy solution.

The financing project “Yao Jingling” is a virtual pharmacy chain service platform based on the S2b2C model. It aims to streamline upstream and downstream information flows, integrate supply chain data and resources, and provide pharmacies with SaaS tools, supply chain integration, operational support, financial services, and member marketing solutions, thereby enhancing their supply chain and service capabilities. The platform currently serves over 10,000 pharmacy clients, with monthly order volumes reaching 70 million.

Financing Plan: Pre-A Round

Funding Amount: 5 million, offering 10% equity

Use of Funds: System Iteration, User Operations, Market Expansion

Funding History: First Round of Financing

Related Link: “Yao Jingling: Data-Empowered Retail Pharmacies, Enabling Independent Stores to Enjoy Chain-Store Management”

https://vcbeat.top/OGNiMWZjNTMyMDUzMjMwODQ1NDJhNmMwNTM3ZGNlN2M=

Renbao Technology is a professional insurtech company that provides enterprises with expert risk management consulting and commercial insurance solutions through data analysis. Leveraging its self-developed business systems for digital operational management, the company delivers comprehensive risk management services to enterprises.

The company undertakes end-to-end transformation of the business processes for enterprise risk outsourcing management, achieving standardized services and digital management. It provides standardized solutions and personalized consulting services based on the categories of risks faced by enterprises and risk scenarios in specific industry segments. Its core business system is compatible with all product offerings from insurance companies, fully supporting the digitalization of business operations and management requirements.

Financing Plan: Pre-A Round Financing

Financing Amount: RMB 5 million

Use of Funds: R&D, Team Operations, Channel Sales, Brand Building

Funding History: First Round of Financing

Related Link: “Specializing in the Blue-Collar Commercial Insurance Market: How Does Renbao Technology Help This Group Mitigate Risks?”

 https://vcbeat.top/NGFiYjEzODBkYjE5MjQzZTdlMjdmNTAzMjVlMTUyZDE=

VibroniX Inc. was founded in the United States in 2014, and its Chinese entity, Weipeng (Suzhou) Medical Device Co., Ltd., was established in 2017. The company is dedicated to commercializing world-leading advanced stimulated Raman scattering microscopy and photoacoustic imaging technologies in China. Its main product lines include microbial antimicrobial susceptibility testing systems, infrared surgical navigation systems, photoacoustic endovascular endoscopes, and tumor margin detection systems, with microbial antimicrobial susceptibility testing equipment being the current key focus of research and development.

The Raman-based ultra-high-speed antimicrobial susceptibility testing (AST) instrument, a key product in our financing portfolio, is VibroniX’s flagship offering. Compared to traditional clinical bacterial AST workflows, coherent Raman ultra-high-speed AST saves time and labor, enabling clinicians to obtain AST results earlier and initiate precise antibiotic interventions for patients more rapidly. Its ideal application scenario is within the clinical laboratory, where technicians can quickly assess the drug resistance of bacterial populations; when coupled with mass spectrometry, it can also identify bacterial species and determine appropriate antibiotic therapies. To date, the company has completed 58 sets of early-stage trials, evaluating 8 common bacterial species and 14 antibiotics that cover 4 major bactericidal and bacteriostatic mechanisms, and has developed the first miniaturized prototype.

Financing Plan: Series A Financing

Financing Amount: $3.5 million (or equivalent in RMB)

Use of Funds: Design finalization, clinical validation trials, and FDA submission fees

Financing History: Angel Round $1.2 million (2016, FreeS Fund)

Related Links: “Self-Developed Coherent Raman Ultra-High-Speed Antimicrobial Susceptibility Tester Enables Accurate Diagnosis of Bacterial Drug Resistance Within Two Hours”

 https://vcbeat.top/YjAyMTU4NzFjZGUwYWUzNGUxZDhkZWE3NWVjYzg4YTM=

For more investment and financing project matchmaking and fundraising promotion services, please contact Xiao Yun at VCBeat.